XTuit Pharmaceuticals
About XTuit Pharmaceuticals
XTuit Pharmaceuticals, Inc. is a biopharmaceutical company developing novel microenvironment-targeted therapeutics that act to silence activated stromal cells, hence turning off multiple pathogenic signaling pathways that play a critical role in driving disease processes in fibrosis and cancer. By acting through pleiotropic mechanisms in the microenvironment, XTuit’s therapeutics resolve inflammation, inhibit tumorigenesis and reduce the production of extracellular matrix – which are all processes that result in fibrosis and hypoxia. In targeting fibrosis, XTuit compounds have the potential to reverse the fibrotic processes underpinning multiple fibrotic diseases. In targeting tumors, XTuit compounds normalize the cancer microenvironment and alleviate hypoxia and solid stress, and creating a more permissive immune environment, thereby offering, in combination with immuno-oncology and other cancer therapies, higher therapeutic success rates. XTuit compounds have been shown to down-regulate stroma-induced tumor and inflammation signaling pathways to overcome treatment resistance. The Company’s proprietary drug development pipeline is integrated with an advanced clinical biomarker platform to enhance and accelerate clinical development.YEAR FOUNDED:
2011
LEADERSHIP:
Founders: Ron Evans, Rakesh Jain, and Robert Langer
CEO: Deborah Dunsire
CSO: Peter Blume-Jensen
CFO: Edward Freedman
3 articles about XTuit Pharmaceuticals
-
Former XTuit Pharmaceuticals Chief Executive Officer Deborah Dunsire has been appointed head of Denmark-based H. Lundbeck A/S.
-
10 Women Biotech CEOs Lead the Charge
6/26/2018
The general consensus is that only about seven to nine percent of chief executive roles in biotech are filled by women. As low as that sounds, it’s better than in the Fortune 500, where only about 4.2 percent are led by female chief executives. -
Former Millennium and FORUM Pharma CEO Resurfaces to Helm Massachusetts Biotech XTuit
3/9/2017